Microbial translocation in HIV infection is associated with dyslipidemia, insulin resistance, and risk of myocardial infarction

Journal of Acquired Immune Deficiency Syndromes

Volumn 64, Issue 5, 2013, Pages 425-433

  Pedersen, Karin K ^a   Pedersen, Maria ^a   Trøseid, Marius ^b   Gaardbo, Julie C ^a   Lund, Tamara T ^a   Thomsen, Carsten ^a   Gerstoft, Jan ^a   Kvale, Dag ^b,c   Nielsen, Susanne D ^a  

^a Rigshospitalet   (Denmark)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

cardiovascular disease; cholesterol; HIV infections; lipopolysaccharides; triglycerides

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; CHOLESTEROL; GLUCOSE; INSULIN; LIPOPOLYSACCHARIDE; LOW DENSITY LIPOPROTEIN; PROTEINASE INHIBITOR; TRIACYLGLYCEROL; ANTIRETROVIRUS AGENT; LIPID;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BODY COMPOSITION; CARDIOVASCULAR RISK; COLORIMETRY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; DYSLIPIDEMIA; FEMALE; FRAMINGHAM RISK SCORE; GLUCOSE METABOLISM; HEART INFARCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIMULUS LYSATE TEST; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; VIRUS INHIBITION; AGED; ANIMAL; BACTERIAL TRANSLOCATION; BLOOD; GLUCOSE TOLERANCE TEST; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; METHODOLOGY; PATHOLOGY; PHOTON ABSORPTIOMETRY; COMPLICATION; DYSLIPIDEMIAS; HIV INFECTIONS; MYOCARDIAL INFARCTION; PROCEDURES;

ABSORPTIOMETRY, PHOTON; ADULT; AGED; ANIMALS; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BACTERIAL TRANSLOCATION; BODY COMPOSITION; CROSS-SECTIONAL STUDIES; DYSLIPIDEMIAS; FEMALE; GLUCOSE TOLERANCE TEST; HIV INFECTIONS; HUMANS; INSULIN RESISTANCE; LIMULUS TEST; LIPIDS; LIPOPOLYSACCHARIDES; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION;

EID: 84891605485     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31829f919d     Document Type: Article

References (65)

1. Lewden C, Chene G, Morlat P, et al. HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr. 2007;46:72-77
2. Lohse N, Hansen AB, Pedersen G, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med. 2007; 146:87-95
3. Deeks SG. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med. 2011;62:141-155
4. Smith C, Sabin CA, Lundgren JD, et al. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS. 2010;24:1537-1548
5. Brenchley JM, Schacker TW, Ruff LE, et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med. 2004;200:749-759
6. Guadalupe M, Reay E, Sankaran S, et al. Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol. 2003;77:11708-11717
7. Mehandru S, Poles MA, Tenner-Racz K, et al. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med. 2004;200:761-770
8. Chege D, Sheth PM, Kain T, et al. Sigmoid Th17 populations, the HIV latent reservoir, and microbial translocation in men on long-term antiretroviral therapy. AIDS. 2011;25:741-749
9. Brenchley JM, Paiardini M, Knox KS, et al. Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections. Blood. 2008;112:2826-2835
10. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12:1365-1371
11. Brenchley JM, Douek DC. HIV infection and the gastrointestinal immune system. Mucosal Immunol. 2008;1:23-30
12. da Silva B, Singer W, Fong IW, et al. In vivo cytokine and neuroendocrine responses to endotoxin in human immunodeficiency virus-infected subjects. J Infect Dis. 1999;180:106-115
13. Sandler NG, Wand H, Roque A, et al. Plasma levels of soluble CD14
14. independently predict mortality in HIV infection. J Infect Dis. 2011;203: 780-790
15. Sandler NG, Douek DC. Microbial translocation in HIV infection: Causes, consequences and treatment opportunities. Nat Rev Microbiol. 2012;10:655-666
16. Troseid M, Lind A, Nowak P, et al. Circulating levels of HMGB1 are correlated strongly with MD2 in HIV-infection: Possible implication for TLR4-signalling and chronic immune activation. Innate Immun. 2013; 19:290-297
17. Giorgi JV, Hultin LE, McKeating JA, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis. 1999;179:859-870
18. Hunt PW, Cao HL, Muzoora C, et al. Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy. AIDS. 2011;25:2123-2131
19. Hunt PW, Martin JN, Sinclair E, et al. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis. 2003;187:1534-1543
20. Troseid M, Nowak P, Nystrom J, et al. Elevated plasma levels of lipopolysaccharide and high mobility group box-1 protein are associated with high viral load in HIV-1 infection: Reduction by 2-year antiretroviral therapy. AIDS. 2010;24:1733-1737
21. Lassenius MI, Pietilainen KH, Kaartinen K, et al. Bacterial endotoxin activity in human serum is associated with dyslipidemia, insulin resistance, obesity, and chronic inflammation. Diabetes Care. 2011;34:1809-1815
22. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56:1761-1772
23. Pussinen PJ, Havulinna AS, Lehto M, et al. Endotoxemia is associated with an increased risk of incident diabetes. Diabetes Care. 2011;34:392-397
24. Manco M, Putignani L, Bottazzo GF. Gut microbiota, lipopolysaccharides, and innate immunity in the pathogenesis of obesity and cardiovascular risk. Endocr Rev. 2010;31:817-844
25. Kelley CF, Kitchen CM, Hunt PW, et al. Incomplete peripheral CD4+
26. cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin Infect Dis. 2009;48:787-794
27. Pedersen M, Pedersen KK, Bruunsgaard H, et al. Cognitive functions in middle aged individuals are related to metabolic disturbances and aerobic capacity: A cross-sectional study. PLoS One. 2012;7:e51132
28. Pedersen KK, Pedersen M, Gaardbo JC, et al. Persisting inflammation and chronic immune activation but intact cognitive function in HIVinfected patients after long term treatment with combination antiretroviral therapy. J Acquir Immune Defic Syndr. 2013;63:272-279
29. Charlson M, Szatrowski TP, Peterson J, et al. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47:1245-1251
30. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 1987;40:373-383
31. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: Comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22:1462-1470
32. Anderson KM, Odell PM, Wilson PW, et al. Cardiovascular disease risk profiles. Am Heart J. 1991;121:293-298
33. Law M, Friis-Moller N, Weber R, et al. Modelling the 3-year risk of myocardial infarction among participants in the data collection on adverse events of anti-HIV drugs (DAD) study. HIV Med. 2003;4:1-10
34. Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA. 2003;289:2978-2982
35. Mocroft A, Reiss P, Gasiorowski J, et al. Serious fatal and nonfatal non- AIDS-defining illnesses in Europe. J Acquir Immune Defic Syndr. 2010; 55:262-270
36. Neuhaus J, Angus B, Kowalska JD, et al. Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV. AIDS. 2010;24:697-706
37. Obel N, Thomsen HF, Kronborg G, et al. Ischemic heart disease in HIVinfected and HIV-uninfected individuals: A population-based cohort study. Clin Infect Dis. 2007;44:1625-1631
38. Triant VA, Lee H, Hadigan C, et al. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92:2506-2512
39. Brown TT, Cole SR, Li X, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med. 2005;165:1179-1184
40. Estes JD, Harris LD, Klatt NR, et al. Damaged intestinal epithelial integrity linked to microbial translocation in pathogenic simian immunodeficiency virus infections. PLoS Pathog. 2010;6:e1001052
41. Jiang W, Lederman MM, Hunt P, et al. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis. 2009;199:1177-1185
42. Merlini E, Bai F, Bellistri GM, et al. Evidence for polymicrobic flora translocating in peripheral blood of HIV-infected patients with poor immune response to antiretroviral therapy. PLoS One. 2011;6:e18580
43. Nowak P, Abdurahman S, Lindkvist A, et al. Impact of HMGB1/TLR ligand complexes on HIV-1 replication: Possible role for flagellin during HIV-1 infection. Int J Microbiol. 2012;2012:263836
44. Nowroozalizadeh S, Mansson F, da Silva Z, et al. Microbial translocation correlates with the severity of both HIV-1 and HIV-2 infections. J Infect Dis. 2010;201:1150-1154
45. Lim A, Amini A, D'Orsogna LJ, et al. Antibody and B-cell responses may control circulating lipopolysaccharide in patients with HIV infection. AIDS. 2011;25:1379-1383
46. Ghoshal S, Witta J, Zhong J, et al. Chylomicrons promote intestinal absorption of lipopolysaccharides. J Lipid Res. 2009;50:90-97
47. Erridge C, Attina T, Spickett CM, et al. A high-fat meal induces lowgrade endotoxemia: Evidence of a novel mechanism of postprandial inflammation. Am J Clin Nutr. 2007;86:1286-1292
48. Levine DM, Parker TS, Donnelly TM, et al. In vivo protection against endotoxin by plasma high density lipoprotein. Proc Natl Acad Sci U S A. 1993;90:12040-12044
49. Casanovas A, Carrascal M, Abian J, et al. Lipoprotein lipase is nitrated in vivo after lipopolysaccharide challenge. Free Radic Biol Med. 2009; 47:1553-1560
50. Fresno M, Alvarez R, Cuesta N. Toll-like receptors, inflammation, metabolism and obesity. Arch Physiol Biochem. 2011;117:151-164
51. Campo R, Dejesus E, Bredeek UF, et al. SWIFT: Prospective 48-week study to evaluate efficacy and safety of switching to emtricitibine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen. Clin Infect Dis. 2013;56:1637-1645
52. Behrens G, Maserati R, Rieger A, et al. Switching to tenofovir/ emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: Effect on lipid profiles. Antivir Ther. 2012;17: 1011-1020
53. Fisher M, Moyle GJ, Shahmanesh M, et al. A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals. J Acquir Immune Defic Syndr. 2009;51:562-568
54. Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: The data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis. 2010;201:318-330
55. Strategies for Management of Anti-Retroviral Therapy/INSIGHT; DAD Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS. 2008;22:F17-F24
56. Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356:1723-1735
57. Limone P, Biglino A, Valle M, et al. Insulin resistance in HIV-infected patients: Relationship with pro-inflammatory cytokines released by peripheral leukocytes. J Infect. 2003;47:52-58
58. Belgardt BF, Bruning JC. CNS leptin and insulin action in the control of energy homeostasis. Ann N Y Acad Sci. 2010;1212:97-113
59. Fernandez-Veledo S, Nieto-Vazquez I, Vila-Bedmar R, et al. Molecular mechanisms involved in obesity-associated insulin resistance: Therapeutical approach. Arch Physiol Biochem. 2009;115:227-239
60. Kino T, Mirani M, Alesci S, et al. AIDS-related lipodystrophy/insulin resistance syndrome. Horm Metab Res. 2003;35:129-136
61. Wiedermann CJ, Kiechl S, Dunzendorfer S, et al. Association of endotoxemia with carotid atherosclerosis and cardiovascular disease: Prospective results from the Bruneck Study. J Am Coll Cardiol. 1999;34:1975-1981
62. Domingo P, Estrada V, Lopez-Aldeguer J, et al. Fat redistribution syndromes associated with HIV-1 infection and combination antiretroviral therapy. AIDS Rev. 2012;14:112-123
63. Qaqish RB, Fisher E, Rublein J, et al. HIV-associated lipodystrophy syndrome. Pharmacotherapy. 2000;20:13-22
64. Bannerman DD, Goldblum SE. Mechanisms of bacterial lipopolysaccharide- induced endothelial apoptosis. Am J Physiol Lung Cell Mol Physiol. 2003;284:L899-L914
65. Cohn JN, Duprez DA, Grandits GA. Arterial elasticity as part of a comprehensive assessment of cardiovascular risk and drug treatment. Hypertension. 2005;46:217-220